Announcement • Mar 30
Novelix Pharmaceuticals Limited Announces Resignation of Jivamohan Divakar Valluri as Non-Executive Director and Changes in Committee Composition, Effective March 30, 2026 Novelix Pharmaceuticals Limited announced that Mr. Jivamohan Divakar Valluri has expressed his intention to resign as a Non-Executive Non-Independent Director of the Company with effect from the close of business hours on March 30, 2026, due to pre-occupation and other personal commitments. Consequent to his resignation, he shall also step down from his positions as a member of the Audit Committee, Nomination & Remuneration Committee, and as Chairperson of the Stakeholders’ Relationship Committee of the Company. The Board of Directors of the Company in its meeting held on March 30, 2026, considered and approved the resignation of Mr. Jivamohan Divakar Valluri (DIN: 09218013) as Non-Executive Director of the Company with effect from closure of business hours on March 30, 2026. Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹0.58 (vs ₹0.15 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.58 (up from ₹0.15 in 3Q 2025). Revenue: ₹484.0m (up ₹431.0m from 3Q 2025). Net income: ₹10.0m (up ₹8.57m from 3Q 2025). Profit margin: 2.1% (down from 2.8% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 125% per year but the company’s share price has only increased by 83% per year, which means it is significantly lagging earnings growth. Announcement • Feb 13
Novelix Pharmaceuticals Limited announced that it has received INR 139.2 million in funding On February 12, 2026, Novelix Pharmaceuticals Limited closed the transaction. The company issued 2,320,000 equity shares of the company at a price per share of INR 60 for gross proceeds of INR 139,200,000. The transaction includes participation from Pavani Vupparapalli for 325,000 shares, Venkataramana Reddy Mallela for 330,000 shares, Venkatarama Rao Bommaraju for 200,000 shares, Suman Rajiv Bihani for 40,000 shares and other investors. The transaction has been approved by the board of directors of the company. 
